Literature DB >> 33429934

Alterations of Nigral Dopamine Levels in Parkinson's Disease after Environmental Enrichment and PACAP Treatment in Aging Rats.

Adel Jungling1, Dora Reglodi1, Gabor Maasz2, Zita Zrinyi2, Janos Schmidt3, Adam Rivnyak1, Gabor Horvath1, Zsolt Pirger2, Andrea Tamas1.   

Abstract

The neuroprotective effects of environmental enrichment and PACAP (pituitary adenylate cyclase-activating polypeptide) are well-described in Parkinson's disease. The aim of our study is to investigate the beneficial effects of these factors in aging parkinsonian rats. Newborn Wistar rats were divided into standard and enriched groups according to their environmental conditions. Standard animals were raised under regular conditions. During the first five postnatal weeks, enriched pups were placed in larger cages with different objects. Aging animals received (1) saline, (2) 6-hydroxidopamine (6-OHDA), or (3) 6-OHDA + PACAP injections into the left substantia nigra (s.n.). On the seventh postoperative day, the left and right s.n. were collected. The s.n. of young and aging unoperated animals were also examined in our experiment. We determined the dopamine (DA) levels by the HPLC-MS technique, while the sandwich ELISA method was used to measure the Parkinson disease protein 7 (PARK7) protein levels. In healthy animals, we found an age-related decrease of DA levels. In aging parkinsonian-enriched rats, the operation did not result in a significant DA loss. PACAP treatment could prevent the DA loss in both the standard and enriched groups. All injured PACAP-treated rats showed remarkably higher protective PARK7 levels. The protective effect of PACAP correlated with the increase of the DA and PARK7 levels.

Entities:  

Keywords:  6-OHDA; PACAP; Parkinson’s disease; aging; enriched environment

Year:  2021        PMID: 33429934      PMCID: PMC7827131          DOI: 10.3390/life11010035

Source DB:  PubMed          Journal:  Life (Basel)        ISSN: 2075-1729


  92 in total

1.  DJ-1 decreases Bax expression through repressing p53 transcriptional activity.

Authors:  Jun Fan; Haigang Ren; Nali Jia; Erkang Fei; Tian Zhou; Peng Jiang; Mian Wu; Guanghui Wang
Journal:  J Biol Chem       Date:  2007-11-26       Impact factor: 5.157

2.  Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress.

Authors:  Sufen Yang; Jun Yang; Zhengqin Yang; Posee Chen; Alison Fraser; Wei Zhang; Hao Pang; Xi Gao; Belinda Wilson; Jau-Shyong Hong; Michelle L Block
Journal:  J Pharmacol Exp Ther       Date:  2006-08-04       Impact factor: 4.030

3.  DJ-1, a novel regulator of the tumor suppressor PTEN.

Authors:  Raymond H Kim; Malte Peters; YingJu Jang; Wei Shi; Melania Pintilie; Graham C Fletcher; Carmela DeLuca; Jennifer Liepa; Lily Zhou; Bryan Snow; Richard C Binari; Armen S Manoukian; Mark R Bray; Fei-Fei Liu; Ming-Sound Tsao; Tak W Mak
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

4.  Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease.

Authors:  Maxime W C Rousseaux; Paul C Marcogliese; Dianbo Qu; Sarah J Hewitt; Sarah Seang; Raymond H Kim; Ruth S Slack; Michael G Schlossmacher; Diane C Lagace; Tak W Mak; David S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

5.  Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells.

Authors:  Anthony Falluel-Morel; Nicolas Aubert; David Vaudry; Magali Basille; Marc Fontaine; Alain Fournier; Hubert Vaudry; Bruno J Gonzalez
Journal:  J Neurochem       Date:  2004-12       Impact factor: 5.372

Review 6.  Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Mol Cell Neurosci       Date:  2012-12-05       Impact factor: 4.314

7.  PACAP inhibits delayed rectifier potassium current via a cAMP/PKA transduction pathway: evidence for the involvement of I k in the anti-apoptotic action of PACAP.

Authors:  Y A Mei; D Vaudry; M Basille; H Castel; A Fournier; H Vaudry; B J Gonzalez
Journal:  Eur J Neurosci       Date:  2004-03       Impact factor: 3.386

8.  Mitochondrial localization of DJ-1 leads to enhanced neuroprotection.

Authors:  Eunsung Junn; Won Hee Jang; Xin Zhao; Byeong Seon Jeong; M Maral Mouradian
Journal:  J Neurosci Res       Date:  2009-01       Impact factor: 4.164

9.  Phosphatidylinositol 3'-OH kinase and protein kinase A pathways mediate the anti-apoptotic effect of pituitary adenylyl cyclase-activating polypeptide in cultured cerebellar granule neurons: modulation by ethanol.

Authors:  Sanjiv V Bhave; Paula L Hoffman
Journal:  J Neurochem       Date:  2004-01       Impact factor: 5.372

Review 10.  Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease.

Authors:  Ludmila P Dolgacheva; Alexey V Berezhnov; Evgeniya I Fedotova; Valery P Zinchenko; Andrey Y Abramov
Journal:  J Bioenerg Biomembr       Date:  2019-05-03       Impact factor: 2.945

View more
  3 in total

Review 1.  Exploring the Pro-Phagocytic and Anti-Inflammatory Functions of PACAP and VIP in Microglia: Implications for Multiple Sclerosis.

Authors:  Margo I Jansen; Sarah Thomas Broome; Alessandro Castorina
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 2.  Enriched Environment and Exercise Enhance Stem Cell Therapy for Stroke, Parkinson's Disease, and Huntington's Disease.

Authors:  Reed Berlet; Dorothy Anne Galang Cabantan; Daniel Gonzales-Portillo; Cesar V Borlongan
Journal:  Front Cell Dev Biol       Date:  2022-03-03

3.  Examination of pituitary adenylate cyclase-activating polypeptide in Parkinson's disease focusing on correlations with motor symptoms.

Authors:  Daniel Pham; Beata Polgar; Tunde Toth; Adel Jungling; Norbert Kovacs; Istvan Balas; Endre Pal; Dora Szabo; Balazs Daniel Fulop; Dora Reglodi; Zalan Szanto; Robert Herczeg; Attila Gyenesei; Andrea Tamas
Journal:  Geroscience       Date:  2022-02-26       Impact factor: 7.581

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.